Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PF-06647263 |
| Synonyms | |
| Therapy Description |
PF-06647263 is an antibody-drug conjugate consisting of an anti-Ephrin-A4 (EFNA4) monoclonal antibody linked to the drug calicheamicin, which may result in tumor growth inhibition (PMID: 26015513, PMID: 30680712). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PF-06647263 | PF06647263|PF 06647263 | PF-06647263 is an antibody-drug conjugate consisting of an anti-Ephrin-A4 (EFNA4) monoclonal antibody linked to the drug calicheamicin, which may result in tumor growth inhibition (PMID: 26015513, PMID: 30680712). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02078752 | Phase I | PF-06647263 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | Terminated | USA | 0 |